目的:  探讨G蛋白信号调节蛋白2（G-protein signaling modulator 2,GPSM2）基因在胰腺癌组织中的表达及其临床意义。方法: 选取54例胰腺癌患者临床石蜡样本制作组织芯片，利用免疫组化检测GPSM2在胰腺癌组织中的表达并分析GPSM2的表达与患者临床病理参数及预后的关系；另选取同期10例新鲜胰腺癌标本及配对的癌旁组织，采用实时RT-PCR法和蛋白质印迹法检测GPSM2 mRNA和蛋白的表达水平。结果：  胰腺癌组织GPSM2 mRNA 及蛋白的表达均明显高于配对的癌旁组织（P均<0.05）。组织芯片检测结果显示，与配对的癌旁组织比较，胰腺癌组织中GPSM2表达明显上调（P<0.05），其高表达（40例）比例达74.1%。GPSM2的表达与患者的肿瘤T分期、TNM分期、分化程度相关：T分期越差(χ2=12.654，P＜0.01)，TNM分期越高(χ2=16.610，P＜0.01)，肿瘤分化程度越差(χ2=10.355，P＜0.01)，其GPSM2表达水平越高。生存分析表明，GPSM2高表达患者的中位生存期明显低于低表达患者（P＜0.05）。结论： 胰腺癌组织GPSM2过表达，其表达与患者的肿瘤T分期、TNM分期、肿瘤分化程度相关,且与胰腺癌的预后有一定相关性。

Objective: To investigate G-protein signaling modulator 2(GPSM2) expression in human pancreatic cancer tissues and to investigate its clinical role and significance. Methods: We made the tissue microarray containing 54 pancreatic cancer samples，as well as the paired normal pancreatic tissues. The relationship between the expression of GPSM2 and the clinicopathological parameters and prognosis of the patients were analyzed by immunohistochemistry. Selected 10 cases of fresh samples of pancreatic cancer，real time PCR were used to detect GPSM2 mRNA in pancreatic cancer and adjacent pancreatic tissues，Western blotting were used to detect the expression of GPSM2 protein in pancreatic cancer and adjacent pancreatic tissue. Results: The expression of GPSM2 mRNA and protein in pancreatic cancer tissue was higher than that in normal tissues (P<0.05). Tissue microarray results showed that GPSM2 expression was significantly up-regulated in pancreatic cancer tissues(P<0.05), and its high expression ratio was 74.1%(40 cases). High GPSM2 expression was associated with larger tumor size(χ2=12.654,P＜0.01), TNM stage(χ2=16.610,P＜0.01)and as well as poor tumor differentiation(χ2=10.355,P＜0.01). Survival analysis showed that the median survival time was significantly lower in patients with high expression of GPSM2 than those with low expression (P<0.05). Conclusion: The overexpression of GPSM2 in pancreatic cancer tissues was closely related to T stage,TNM stage and poor tumor differentiation, which is related to the prognosis of the patients with pancreatic cancer.